newswire, breaking biotechnology and pharma news

Wednesday, March 7, 2012

Vermillion (NASDAQ: VRML) Closes up over 125% as NSDAQ's Top Percentage Gainer

New York, New York - March 7, 2012 -, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for molecular diagnostics company, Vermillion, Inc. (NASDAQ: VRML ), gaining 125.56% on the day to close at $ 3.00, up 1.67 on over 10 Million shares. The stock continued its rally in after hours trading.

The stock was NASDAQ's top percentage gainer on a day that NASDAQ closed down over 40 points.

The Company reported news that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has voted to approve an application for a Category 1 CPT code for its OVA1® test, which is designed to help differentiate benign versus malignant ovarian masses.

Vermillion, Inc. (VRML)

Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at

More Info:

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts

Research biotech stocks at the Investor Ideas Biotech stocks Directory:

Become an Member

Follow on Twitter!/Investorideas
Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source -

1 comment:

  1. Hi there,

    I apologize for contacting you via the comments, but couldn't find your email anywhere! I have been speaking with Ms. Vanzant of Clean Energy Stocks, and she recently posted a few tools I've built on CleanTech Venture Capital Firms. I wanted to show you a few similar resources for biotech firms, would you be alright with my sending you the links?

    Let me know,

    Noah Greenberg